Thinking about moving from tirzepatide to retatrutide? Here is what the science says right now

What the phase 2 retatrutide trial actually reported

The trial that sparked most of the interest was published in the New England Journal of Medicine in June 2023. It was a phase 2 dose-finding study, smaller in scale than a pivotal licensing trial, with around 338 adults with obesity and without diabetes. Participants receiving the highest tested dose of retatrutide (12mg weekly) saw an average body-weight reduction of roughly 17% at 24 weeks, rising to approximately 24.2% at 48 weeks. Those are striking numbers for a phase 2 setting, and they reflect the triple-receptor mechanism: by adding glucagon receptor activation alongside GIP and GLP-1, retatrutide appears to increase energy expenditure as well as reducing appetite, a different physiological lever from what tirzepatide pulls alone.

The caveat matters, though. Phase 2 trials optimise dose and assess tolerability; they are not designed to give the definitive efficacy picture that a full phase 3 programme delivers. Side-effect rates at the higher doses were meaningful, with gastrointestinal effects the most common, broadly similar in character to those seen with GLP-1 medicines already on the market. No regulatory body has reviewed the phase 3 data yet, because phase 3 is still underway.

For context on what licensed evidence looks like, the tirzepatide clinical programme involved thousands of adults across its SURMOUNT trials before MHRA authorisation, that level of scrutiny is what retatrutide still needs to complete.

Why moving between these two medicines is not yet a clinical option in the UK

The MHRA licences medicines for specific indications after reviewing the full dataset from phase 3 trials; it has not received, let alone approved, a marketing authorisation application for retatrutide as of summer 2026. That means no UK prescriber can lawfully prescribe it for weight management through a standard route, and no GPhC-registered pharmacy can dispense it as a licensed product.

This is not a bureaucratic technicality. Licensing exists precisely to establish that a medicine's benefit-risk profile is understood across a large, diverse patient group, not just a phase 2 cohort. The MHRA's framework for prescription medicines means that until that process completes, there is no verified dosing schedule, no confirmed contraindication list and no agreed stopping criteria for retatrutide in weight management, all things that a prescriber needs before advising a patient to switch. For anyone curious about how retatrutide differs mechanistically from tirzepatide, those distinctions are real and interesting, but they do not yet translate into a prescribable clinical pathway.

People sometimes ask whether compounded or imported versions of retatrutide might be accessible outside that framework. The MHRA has been clear that obtaining prescription medicines from sources outside the licensed supply chain carries serious risks, and the counterfeit market for injectable weight-loss medicines in the UK is active and documented. Buying Mounjaro online from a legitimate, GPhC-registered source is one thing; sourcing an unlicensed experimental medicine from an unverified seller is something categorically different.

What this means for your current tirzepatide treatment

If you are on Mounjaro and wondering whether to wait for retatrutide, the practical answer is that there is no clear timeline. Phase 3 trials take time, regulatory review takes more time, and NHS commissioning decisions follow after that. The treatment available to you today (Mounjaro (tirzepatide)) is the only dual-agonist weight-management medicine licensed in the UK, backed by NICE appraisal TA1026 published in December 2024, and with a trial programme that followed thousands of adults for 72 weeks or more.

Pausing or stopping your current treatment on the basis of a medicine that does not yet exist in a licensed form is unlikely to serve your health goals. If you are on Mounjaro and not seeing the progress you hoped for, the right question is whether your dose, your lifestyle support or your overall clinical plan needs reviewing, not whether an unlicensed successor might theoretically do better. Our clinical team reviews each patient's case individually; that kind of conversation belongs in a proper clinical setting, not a forum thread about a phase 3 trial.

It is also worth knowing that tirzepatide continues to produce some of the strongest weight-loss results of any licensed medicine. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, reported greater average weight reduction with tirzepatide than with semaglutide 2.4mg over 72 weeks in a head-to-head study, a meaningful result for people comparing their options. You can explore the full picture of weight-loss treatment options to see where tirzepatide sits relative to other licensed medicines.

How to stay informed without being misled

Retatrutide generates a lot of online discussion, and some of it conflates phase 2 data with clinical reality. A few things to keep in mind when reading about it. First, weight-loss percentages from phase 2 trials are not directly comparable to those from phase 3 trials in different populations, the patient selection, duration and statistical methods differ. Second, no trial has yet compared retatrutide head-to-head with tirzepatide in the same study; the suggestion that it is definitively superior is, at present, an inference across trials rather than a finding within one. Third, if you see anyone offering retatrutide injections for purchase, that is a significant red flag, report suspect sellers via the MHRA Yellow Card scheme.

The question of mixing tirzepatide and retatrutide also comes up, and if you want to understand the full picture of why combining these two medicines is such a concern, our page on mixing retatrutide and tirzepatide explains the risks in detail; the short answer is that combining GLP-1 class medicines is not supported by evidence and carries additive risk, something to raise with a prescriber, not to attempt independently. If you have questions about your current treatment or want to understand your options properly, our FAQs cover many of the most common ones, or you can get in touch with our team directly. And if you are not yet on treatment and are wondering where to start, a free consultation is the right first step, no pressure, just a real clinical conversation. Check your eligibility and start your free consultation to speak with one of our GPhC-registered prescribers.